Secondly, some RCTs lacked detailed reporting on the arrhythmia history of participants, such as paroxysmal AF/AFL and persistent AF/AFL, which might complicate the accurate evaluation of SGLT2 inhibitors’ effects. The gene discussed is SLC5A2; the disease is Arrhythmia.